Brolucizumab: What’s new and newer about it?

ANDERSON ,William J.; AKDUMAN ,Levent

doi:10.37845/ret.vit.2020.29.52

William J. ANDERSON

(Saint Louis University, Department of Ophthalmology, St. Louis, Missouri, United States of America)

Levent AKDUMAN

(Saint Louis University, Department of Ophthalmology, St. Louis, Missouri, United States of America)

Retina-Vitreus

Yıl: 2020Cilt: 29Sayı: 4ISSN: 1300-1256 / 2717-7149Sayfa Aralığı: 287 - 291Metin Dili: İngilizce

DOI: https://doi.org/10.37845/ret.vit.2020.29.52

56 0

İngilizce

Brolucizumab: What’s new and newer about it?

Abstract: Brolucizumab is the newest anti-vascular endothelial growth factor (anti-VEGF) drug approved for use. The aim of this review is to review the HAWK/HARRIER clinical trials, examine post-marketing experience with the drug, and evaluate the packaging/procedural differences with brolucizumab. Brolucizumab is a more potent and longer lasting anti-VEGF agent, and is an important agent that may be used in the treatment of neovascular age-related macular degeneration. Retinal vasculitis is a rare but very serious complication of brolucizumab that the patient and physician must be aware of.

Keywords:

Subject Area:

Belge Türü: DergiMakale Türü: EditoryalErişim Formatı: Erişime Kapalı

1. Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020;127:72-84.
2. Avaylon J, Lee S, Gallemore RP. Case Series on Initial Responses to Intravitreal Brolucizumab in Patients with Recalcitrant Chronic Wet Age-Related Macular Degeneration. Int Med Case Rep J. 2020;13:145-52.
3. Witkin AJ, Hahn P, Murray TG, et al. Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab. J Vitreoretin Dis. 2020;4:269-79.
4. https://www.brolucizumab.info/post-marketing-data. Accessed September 30th, 2020.
5. https://www.brolucizumab.info/sites/brolucizumab_info/fi les/2020-07/ASRS_SRC_report.pdf. Accessed August 31st, 2020.
6. https://www.novartis.com/news/novartis-provides-update-use-and-safety-beovu-patients-wet-amd. Accessed September 30th, 2020.
7. Comparison of Age-related Macular Degeneration Treatments Trials Research G, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388-98.
8. Gianniou C, Dirani A, Jang L, Mantel I. Refractory Intraretinal or Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Intravitreal Ranizubimab: Functional and Structural Outcome. Retina. 2015;35:1195-201.
9. Guymer RH, Markey CM, McAllister IL, et al. Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results. Ophthalmology. 2019;126:723-34.
10. Hsu J, Patel SN, Wolfe JD, et al. Effect of Adjuvant Topical Dorzolamide-Timolol vs Placebo in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. JAMA Ophthalmol. 2020.
11. Byeon SH, Kwon OW, Song JH, Kim SE, Park YS. Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol-Dorzolamide). Graefes Arch Clin Exp Ophthalmol. 2009;247(1):35-42.
12. Casini G, Dal Monte M, Fornaciari I, Filippi L, Bagnoli P. The beta-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases. Prog Retin Eye Res. 2014;42:103-29.
13. Bontzos G, Bagheri S, Ioanidi L, et al. Nonresponders to Ranibizumab Anti-VEGF Treatment Are Actually Short-term Responders: A Prospective Spectral-Domain OCT Study. Ophthalmol Retina. 2019.